James Berkshire Sells 2,668 Shares of IQVIA (NYSE:IQV) Stock

IQVIA Holdings Inc. (NYSE:IQV) insider James Berkshire sold 2,668 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

IQVIA Stock Performance

Shares of IQV opened at $267.34 on Friday. The firm has a market cap of $44.00 billion, a P/E ratio of 33.17, a PEG ratio of 2.29 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $271.80. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The firm’s 50 day moving average price is $230.54 and its two-hundred day moving average price is $192.66.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

Institutional Trading of IQVIA

Several institutional investors have recently added to or reduced their stakes in IQV. International Assets Investment Management LLC bought a new position in IQVIA during the 4th quarter worth $27,000. Compass Financial Management LLC acquired a new position in shares of IQVIA in the second quarter valued at about $27,000. Gilpin Wealth Management LLC bought a new position in IQVIA during the fourth quarter worth about $27,000. CrossGen Wealth LLC acquired a new stake in IQVIA in the 4th quarter worth about $28,000. Finally, Financial Freedom LLC bought a new stake in IQVIA in the 1st quarter valued at about $25,000. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. lifted their price target on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. BMO Capital Markets boosted their target price on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, August 29th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.62.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.